Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17122217 | 0.91 | GPR119 (0.84) | GPR119HDAC4HDAC6 | |
| SCHEMBL12603064 | 0.90 | GPR119 (0.82) | GPR119HDAC4USP30HDAC6TSHR | |
| SCHEMBL387143 | 0.89 | GPR119 (0.80) | GPR119TSHRSMN1; SMN2LMNARECQL | |
| SCHEMBL389765 | 0.89 | GPR119 (0.80) | GPR119HDAC4USP30HDAC6TSHR | |
| SCHEMBL390187 | 0.89 | GPR119 (0.79) | GPR119TSHRSMN1; SMN2LMNARECQL | |
| SCHEMBL387294 | 0.88 | GPR119 (0.79) | GPR119TSHRSMN1; SMN2LMNARECQL | |
| SCHEMBL389587 | 0.88 | GPR119 (0.79) | GPR119TSHRSMN1; SMN2LMNARECQL | |
| SCHEMBL4416063 | 0.88 | GPR119 (0.78) | GPR119HDAC4HDAC6SMN1; SMN2LMNA | |
| SCHEMBL4420442 | 0.87 | GPR119 (0.77) | GPR119HDAC4 | |
| SCHEMBL391143 | 0.87 | GPR119 (0.76) | GPR119HDAC4USP30HDAC6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 333 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207147-B2 | Heterocyclic derivatives as GPCR receptor agonists | PROSIDION LIMITED (GB) | 2012-06-26 | — | — | US | claimed |
| US-20260077012-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | EPITRACKER INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12427179-B2 | Compositions and methods for diagnosis and treatment of neurodegenerative diseases | Epitracker, Inc. (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4590287-A1 | COMPOSITIONS AND METHODS FOR IMPROVING GUT PERMEABILITY | Brightseed, Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20250205182-A1 | COMPOSITIONS AND METHODS FOR IMPROVING GUT PERMEABILITY | BRIGHTSEED, INC. | 2025-06-26 | — | — | US | disclosed |
| US-20250000804-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | ANJI PHARMA (US) LLC | 2025-01-02 | — | — | US | disclosed |
| US-20240307336-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | EPITRACKER INC (US) | 2024-09-19 | — | — | US | disclosed |
| US-20240277649-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | EPITRACKER INC (US) | 2024-08-22 | — | — | US | disclosed |
| EP-4410285-A2 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF METABOLIC SYNDROME | Government Of The United States Of America As Represented By The Secretary Of the Navy (US) | 2024-08-07 | — | — | EP | disclosed |
| EP-4410380-A2 | DELAYED-RELEASE COMPOSITION COMPRISING BIGUANIDE | Anji Pharmaceuticals Inc. (US) | 2024-08-07 | — | — | EP | disclosed |
| WO-2008017381-A1 | ARYLAMINOARYL-ALKYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, PROCESSES FOR PREPARING THEM, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THEIR USE | SANOFI-AVENTIS (FR) | 2008-02-14 | — | — | WO | disclosed |
| WO-2007120702-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| EP-1808168-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | Arena Pharmaceuticals, Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20070072804-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070072803-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS (US) | 2007-03-29 | — | — | US | disclosed |
| EP-1758565-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | Arena Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | disclosed |
| EP-1711491-A1 | HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS | Prosidion Limited (GB) | 2006-10-18 | — | — | EP | disclosed |
| WO-2006076231-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060154866-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
| WO-2005061489-A1 | HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072803-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | GLP1R, GPR119, GIPR | GPR119 2/4885HDAC4 573/4885USP30 2828/4885 |
| US-20070072804-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | GLP1R, GPR119, GIPR | GPR119 2/4885HDAC4 573/4885USP30 2828/4885 |
| US-20260077012-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | CD4, COL2A1, MMP1 | GPR119 2977/4885HDAC4 3543/4885USP30 3844/4885 |
| US-20250000804-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | SLC5A2, SLC10A1, GPR119 | GPR119 3/4885HDAC4 1134/4885USP30 2435/4885 |
| US-20250205182-A1 | COMPOSITIONS AND METHODS FOR IMPROVING GUT PERMEABILITY | FABP2, VIP, SI | GPR119 10/4885HDAC4 2884/4885USP30 3121/4885 |
| US-20060154866-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | GLP1R, GPR119, GIPR | GPR119 2/4885HDAC4 573/4885USP30 2828/4885 |
| US-20240277649-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | FABP1, FASN, GPR119 | GPR119 3/4885HDAC4 1018/4885USP30 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.